Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally

Key Points New York City-based Armistice Capital sold 2,152,000 shares of Travere Therapeutics for an estimated $29.3 million in the third quarter. At quarter-end, the fund reporting holding 6.7 million shares of Travere Therapeutics valued at $160.7 million. The position now represents 2% of fund assets, making it Armistice's second-largest holding. These 10 stocks could mint the next wave of millionaires › On Friday, New York City-based Armistice Capital disclosed it sold 2,152,000 shares of Tr ...